|
Basic Characteristics of Mutations
|
|
Mutation Site
|
Q498R |
|
Mutation Site Sentence
|
This loss of binding can be attributed to shared mutations across all variants of concern, namely Q498R, N501Y, Y505H in FQPTNGVGY, Y505H in GYQPYRVVVLSF, and P681H in SPRRARSVA. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
|
|
Standardized Encoding Gene
|
|
|
Genotype/Subtype
|
Omicron |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
COVID-19
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
39455652
|
|
Title
|
In-silico evaluation of the T-cell based immune response against SARS-CoV-2 omicron variants
|
|
Author
|
Sharma S,Roy D,Cherian S
|
|
Journal
|
Scientific reports
|
|
Journal Info
|
2024 Oct 25;14(1):25413
|
|
Abstract
|
During of COVID-19 pandemic, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has continuously evolved, resulting in the emergence of several new variants of concerns (VOCs) with numerous mutations. These VOCs dominate in various regions due to increased transmissibility and antibody evasion, potentially reducing vaccine effectiveness. Nonetheless, it remains uncertain whether the recent SARS-CoV-2 VOCs have the ability to circumvent the T cell immunity elicited by either COVID-19 vaccination or natural infection. To address this, we conducted in-silico analysis to examine the impact of VOC-specific mutations at the epitope level and T cell cross-reactivity with the ancestral SARS-CoV-2. According to the in-silico investigation, T cell responses triggered by immunization or prior infections still recognize the variants in spite of mutations. These variants are expected to either maintain their dominant epitope HLA patterns or bind with new HLAs, unlike the epitopes of the ancestral strain. Our findings indicate that a significant proportion of immuno-dominant CD8 + and CD4 + epitopes are conserved across all the variants, implying that existing vaccines might maintain efficacy against new variations. However, further in-vitro and in-vivo studies are needed to validate the in-silico results and fully elucidate immune sensitivities to VOCs.
|
|
Sequence Data
|
-
|
|
|